Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Debt (2018 - 2021)

Rein Therapeutics (RNTX) has disclosed Non-Current Debt for 3 consecutive years, with $55000.0 as the latest value for Q1 2021.

  • On a quarterly basis, Non-Current Debt changed N/A to $55000.0 in Q1 2021 year-over-year; TTM through Mar 2021 was $55000.0, a N/A change, with the full-year FY2020 number at $219000.0, changed N/A from a year prior.
  • Non-Current Debt was $55000.0 for Q1 2021 at Rein Therapeutics, down from $219000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $5.3 million in Q4 2018 to a low of $55000.0 in Q1 2021.
  • A 3-year average of $2.1 million and a median of $336000.0 in 2020 define the central range for Non-Current Debt.